AC
TGTX icon

Armistice Capital’s TG Therapeutics TGTX Stock Holding History

Armistice Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-768,000
Closed -$7.56M – 94
2020
Q1 		$7.56M Sell
768,000
-32,000
-4% -$404K 0.47% 62
2019
Q4 		$8.88M Buy
+800,000
New +$6.08M 0.51% 51

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Armistice Capital's TGTX Position: Q2 2020 in Review

Armistice Capital sold out of TG Therapeutics (TGTX) in Q2 2020, closing a stake of 768,000 shares — an estimated $7.56M sold.

Armistice Capital first reported a position in TGTX in Q4 2019 and held it in 2 quarters. The position peaked at $8.88M in Q4 2019. 175 funds tracked by Wall St. Rank hold TGTX as of Q2 2020.

  • Armistice Capital reported no remaining TG Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Armistice Capital sold 768,000 TG Therapeutics shares in Q2 2020, an estimated $7.56M.
  • Armistice Capital first reported a position in TG Therapeutics in Q4 2019 and held it in 2 quarters.
  • Armistice Capital's TG Therapeutics position peaked at $8.88M in Q4 2019.
  • 175 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2020.

Based on Armistice Capital's 13F filing for Q2 2020, filed 14 Aug 2020.